Home Newsfeeds Baird Downgrades Fastenal to Neutral, Announces $48 Price Target

Baird Downgrades Fastenal to Neutral, Announces $48 Price Target

Baird analyst David Manthey downgrades Fastenal (NASDAQ:FAST) from Outperform to Neutral and announces $48 price target.

byBenzinga Newsdesk

July 14, 2022

1 minute read

Baird analyst David Manthey downgrades Fastenal (NASDAQ:FAST) from Outperform to Neutral and announces $48 price target.

Nuvectis Pharma, Inc. Announces A Collaboration With Mayo Clinic To Evaluate NXP800 In An Investigator-Sponsored Clinical Trial In Cholangiocarcinoma

By Benzinga Newsdesk

December 18, 9:06 AM

Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by investigators from Mayo

NVCT

Rising Interest Rates Lead To Big Bank Profit Gains: Are There Hints Of Inbound Recession?

By AJ Fabino

January 14, 12:30 PM

Investors waiting for another round of earnings were greeted by Friday’s reports from the nation’s biggest banks showing that profits rose across the sector, boosted by the Federal Reserve’s high-interest rate environment.

BAC